MARKET

MRUS

MRUS

Merus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.05
+0.36
+3.08%
Closed 16:00 09/25 EDT
OPEN
11.86
PREV CLOSE
11.69
HIGH
12.15
LOW
11.75
VOLUME
35.70K
TURNOVER
--
52 WEEK HIGH
20.91
52 WEEK LOW
10.18
MARKET CAP
350.14M
P/E (TTM)
-4.6541
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Merus (MRUS) Looks Good: Stock Adds 7% in Session
Merus (MRUS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Zacks · 09/16 15:03
Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Simply Wall St. · 08/24 19:33
Merus to Present at the 2020 Wedbush PacGrow Healthcare Conference
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lu
GlobeNewswire · 08/07 12:30
Merus EPS beats by $0.12, misses on revenue
Merus (NASDAQ:MRUS): Q2 GAAP EPS of -$0.54 beats by $0.12. Revenue of $6.1M (-4.1% Y/Y) misses by $1.61M. Press Release
seekingalpha · 08/07 02:05
Merus Announces Financial Results for the Second Quarter and Provides Business Update
– Lead program Zenocutuzumab remains on track – – Dr. Andrew Joe appointed Chief Medical Officer – – Merus extends cash runway into 2H 2022 –UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”,
GlobeNewswire · 08/06 20:07
Seeking Alpha Catalyst Watch
seekingalpha · 08/01 01:00
Merus nabs US Orphan Drug tag for Zeno in pancreatic cancer
Seeking Alpha · 07/27 15:40
Merus Announces FDA Orphan Drug Designation Of Zenocutuzumab For The Treatment Of Pancreatic Cancer
Benzinga · 07/27 12:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRUS. Analyze the recent business situations of Merus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRUS stock price target is 19.50 with a high estimate of 23.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 54
Institutional Holdings: 21.26M
% Owned: 73.16%
Shares Outstanding: 29.06M
TypeInstitutionsShares
Increased
9
2.40M
New
22
-386.36K
Decreased
9
1.43M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.00%
Pharmaceuticals & Medical Research
+1.53%
Key Executives
Non-Executive Chairman/Independent Director
Anand Mehra
President/Chief Executive Officer/Chief Financial Officer/Executive Director
Sven Lundberg
Non-Executive Vice Chairman/Non-Executive Director
Gregory Perry
Chief Technology Officer
John de Kruif
General Counsel
Peter Silverman
Other
Alexander Bakker
Other
Lex Bakker
Other
Andrew Joe
Other
Hui Liu
Non-Executive Independent Director
Mark Iwicki
Other
L. Andres Sirulnik
Non-Executive Independent Director
Leonard Kanavy
Non-Executive Independent Director
Paolo Pucci
Non-Executive Independent Director
Victor Sandor
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MRUS
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Merus NV stock information, including NASDAQ:MRUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRUS stock methods without spending real money on the virtual paper trading platform.